Expression of the survivin-2B splice variant related to the progression of colorectal carcinoma

Journal of the Korean Surgical Society

Volumn 80, Issue 6, 2011, Pages 404-411

  Cho, Gyu Seok ^a   Ahn, Tae Sung ^a   Jeong, Dongjun ^b   Kim, Jae Jun ^b   Kim, Chang Jin ^b   Cho, Hyun Deuk ^b   Park, Dong Kook ^c   Baek, Moo Jun ^a,b  

^a The Catholic University of Korea   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Colorectal neoplasms; Quantitative RT PCR; Survivin variant

Indexed keywords

EID: 79959439255     PISSN: 12260053     EISSN: 20930488     Source Type: Journal    
DOI: 10.4174/jkss.2011.80.6.404     Document Type: Article

References (26)

1. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002;30:13-9.
2. Ng CC, Koyama K, Okamura S, Kondoh H, Takei Y, Nakamura Y. Isolation and characterization of a novel TP53-inducible gene, TP53TG3. Genes Chromosomes Cancer 1999;26:329-35. (Pubitemid 29529578)
3. Weng MW, Lai JC, Hsu CP, Yu KY, Chen CY, Lin TS, et al. Alternative splicing of MDM2 mRNA in lung carcinomas and lung cell lines. Environ Mol Mutagen 2005;46:1-11.
4. Yukitake H, Furusawa M, Taira T, Iguchi-Ariga SM, Ariga H. AAT-1, a novel testis-specific AMY-1-binding protein, forms a quaternary complex with AMY-1, A-kinase anchor protein 84, and a regulatory subunit of cAMP-dependent protein kinase and is phosphorylated by its kinase. J Biol Chem 2002;277:45480-92. (Pubitemid 36159158)
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21. (Pubitemid 27353455)
6. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-6. (Pubitemid 40343130)
7. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000;35:550-3.
8. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002;100:30-6. (Pubitemid 34602061)
9. Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004;216:147-55. (Pubitemid 39463318)
10. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003;99:738-45. (Pubitemid 37168044)
11. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 2004;28:487-94. (Pubitemid 38453061)
12. O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, Glynn S, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201:225-36. (Pubitemid 37357172)
13. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4. (Pubitemid 28521163)
14. Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 2004;10:2886-9. (Pubitemid 39303012)
15. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 2005;13: 891-7.
16. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
17. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 1997;48:267-81. (Pubitemid 27101830)
18. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401. (Pubitemid 26240369)
19. Jäättelä M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248:30-43. (Pubitemid 29393927)
20. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59. (Pubitemid 29043977)
21. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-4. (Pubitemid 27317977)
22. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20. (Pubitemid 28551107)
23. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-70. (Pubitemid 24338467)
24. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102. (Pubitemid 30035627)
25. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61:8664-7. (Pubitemid 34013874)
26. Krieg A, Mahotka C, Krieg T, Grabsch H, Müller W, Takeno S, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002;86:737-43. (Pubitemid 34250816)